Why 2011 Could Be a Big Year for Pharmaceutical M&A
Apr 24, 2011 | Posted by: roboblogger | Full story: Seeking Alpha
Just a couple of weeks after Gilead Sciences announced that it would be raising the prices of its leading HIV drugs, the company issued first quarter earnings numbers that were significantly below analyst expectations.
Good the bastards cause as much harm as good with their poison product. I hope they go bankrupt.
|Divide over HIV prevention drug Truvada persists||Apr 6||juls||2|
|FDA advisors back new Hepatitis C drug||Oct '13||WARNING FDA APPROVED||1|
|Gilead's Sofosbuvir for Hepatitis C Meets Prima... (Feb '13)||Feb '13||Axel||1|
|HIV11: Stribild Matches Efficacy and Tolerabili... (Jan '13)||Jan '13||kmc2749||1|
|FDA approves first pill to help prevent HIV (Jul '12)||Jul '12||k-wire||3|
|FDA Panel OKs Truvada for HIV Prevention (May '12)||May '12||KittenKoder||5|
|FDA panel backs first pill to block HIV infection (May '12)||May '12||P_Smith||6|